April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Rebound increase in VEGF levels following intravitreal injection of bevacizumab in a child
Author Affiliations & Notes
  • Emily Han Shao
    Faculty of Medicine, Imperial College London, London, United Kingdom
    Ophthalmology, Royal Surrey County Hospital NHS Foundation Trust, Guildford, United Kingdom
  • Ying L Dong
    Kingston Hospital NHS Foundation Trust, Kingston Upon Thames, United Kingdom
  • Reena Dave
    Kingston Hospital NHS Foundation Trust, Kingston Upon Thames, United Kingdom
  • Simon Richard Taylor
    Faculty of Medicine, Imperial College London, London, United Kingdom
    Ophthalmology, Royal Surrey County Hospital NHS Foundation Trust, Guildford, United Kingdom
  • Vasuki Sivagnanavel
    Kingston Hospital NHS Foundation Trust, Kingston Upon Thames, United Kingdom
  • Footnotes
    Commercial Relationships Emily Shao, None; Ying Dong, None; Reena Dave, None; Simon Taylor, None; Vasuki Sivagnanavel, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1939. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Emily Han Shao, Ying L Dong, Reena Dave, Simon Richard Taylor, Vasuki Sivagnanavel; Rebound increase in VEGF levels following intravitreal injection of bevacizumab in a child. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1939.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Vascular endothelial growth factor (VEGF) is one of the most potent cytokines targeted in anti-angiogenic therapies and anti-VEGF agents have become widely used in the treatment of macular degeneration and retinal vascular disease. However, the effects of intraocular administration of anti-VEGF drugs on systemic levels remain controversial. This may be important, as VEGF is essential for angiogenesis and thus the function of the developing brain, lung, and kidneys in children, as well as in maintaining normal organ function in adults. In this study we analysed systemic changes in VEGF levels in a child with congenital toxoplasmosis who was treated with a course of bevacizumab injections for a secondary choroidal neovascular membrane.

 
Methods
 

Serum samples were obtained from a nine-year-old child with a choroidal rupture from blunt trauma, who developed a secondary choroidal neovascular membrane and was then treated with 5 bevacizumab injections over a period of 12 months. Peripheral venous blood samples were taken at each visit and centrifuged at 3,000 rpm for 10 minutes followed by being stored at - 70°C until analysis. Serum VEGF 165 levels were determined using enzyme-linked immunosorbent assay (R&D systems, UK) both pre and post immunodepletion to remove complexed VEGF.

 
Results
 

Serum VEGF 165 levels were initially suppressed by intravitreal bevacizumab, with levels remaining low for 11 weeks after the end of the first course of two injections (Figure 1). Levels then rebounded significantly and remained high despite three further intravitreal bevacizumab injections, before returning to baseline at 12 months.

 
Conclusions
 

These results suggest that repeated intravitreal bevacizumab injections initially lead to a decrease in systemic VEGF levels, but that there may be a later rebound increase to above baseline levels. This may be of particular clinical significance in children as VEGF is vital in the development of major organs, but VEGF metabolism is also known to be important in the maintenance of normal organ function in adults.

 
 
Figure 1. Changes in serum concentration of VEGF (pg/ml) with repeated intravitreal injections of bevacizumab.
 
Figure 1. Changes in serum concentration of VEGF (pg/ml) with repeated intravitreal injections of bevacizumab.
 
Keywords: 453 choroid: neovascularization • 503 drug toxicity/drug effects • 609 neovascularization  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×